Publikationen 2015

86.  Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R, SAKK and the German CML Study Group.  Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.  Ann Hematol. 2015 Dec;94(12): 2015-24 2015-24.

85.  Stilgenbauer S.  Prognostic markers and standard management of chronic lymphocytic leukemia.  Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):368-77.

84.  Zugmaier G, Gökbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, Horst HA, Marks R, Faul C, Diedrich H, Reichle A, Brüggemann M, Holland C, Schmidt M, Einsele H, Bargou RC, Topp MS.  Long-term survival and T-Cell kinetics in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia who achieved minimal residual disease response following treatment with Anti-CD19 BiTE® antibody construct blinatumomab.  Blood. 2015 Dec 10;126(24):2578-84.    

83.  Opel D, Schnaiter A, Dodier D, Jovanovic M, Gerhardinger A, Idler I, Mertens D, Bullinger L, Stilgenbauer S, Fulda S.  Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.  Int J Cancer. 2015 Dec 15;137(12):2959-70.

82.  van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group. Urban Ch, Meister B, Fink FM, Kerbl R, Stollinger O, Schmitt K, Ebetsberger G, Jones N, Ladenstein R, Gadner H, Maes P, Brichard B, Mazzeo F, Gil T, Dhooge C, Vermorken JB, Klein A, Kruseova J, Krarup-Hansen A, Nielsen O, Capra M, Pautard B, Rialland X, Maillart P, Plouvier E, Vérité C, Bui N'guyen B, Boutard P, Delcambre C, Bay JO, Demeocq F, Couillault G, Isambert N, Plantaz D, Desfachelles AS, Piguet C, Marec-Bérard P, Blay JY, Gentet JC, Duffaud F, Bertucci F, Sirvent N, Schmitt C, Rios M, Corradini N, Rolland F, Deville A, Thyss A, Michon J, Tabone MD, Pierga JY, Millot F, Munzer M, Edan C, Vannier JP, Guillemet C, Brun E, Berger C, Castex MP, Roche H, Lejars O, Linassier C, Oberlin O, Le Cesne A, Bauer S, Ebeling P, Flasshove M, Hartmann JT, Reichardt P, Mertens R, Osieka R, Gnekow A, Schlimok G, Henze G, Thuss-Patience P, Wickmann L, Reichardt P, Potenberg J, Reichardt P, Bode U, Schmidt-Wolf IG, Eberl W, Wolff T, Pekrun A, Hofmann A, Andler W, Schneider D, Lauterbach I, Zickler P, Göbel U, Borkhardt A, Sauerbrey A, Holter W, Bauer S, Ebeling P, Flasshove M, Eggert A, Klingebiel T, Niemeyer C, Heinz J, Reiter A, Rummel M, Runde V, Lakomek M, Trümper L, Beck J, Dölken G, Lindemann HW, Körholz D, Schmoll HJ, Schneppenheim R, Hossfeld DK, Bokemeyer C, Keles H, Welte K, Klein C, Kulozik A, Egerer G, Cyran J, Strumberg D, Freier W, Graf N, Pfreundschuh M, Gruhn B, Leipold A, Bentz M, Wehinger H, Schrappe M, Nolte H, Berthold F, Wolf J, Sternschulte W, Voelpel S, Frieling T, Moessner J, Selle D, Bucsky D, Bartels H, Mohren M, Fischer T, Kluba U, Gutjahr P, Dittrich M, Reiter S, Dürken M, Neubauer A, Beyer J, Christiansen H, Erdlenbruch B, Burdach S, Schmid I, Meyer zum Büschenfelde C, Peschel C, Oduncu F, Jürgens H, Berdel W, Held H, Hofmann-Wackersreuther G, Müller H, Peters O, Andreesen R, Krause S, Heits F, Geib-König R, Kasbohm M, Bürger D, Burghard R, Dickerhoff R, Bielack S, Feddersen I, Clemens MR, Handgretinger R, Hartmann JT, Debatin KM, Mayer-Steinacker R, Schoengen A, Schlegel P, Lee V, Chik KW, van den Berg H, Rodenhuis S, Gelderblom AJ, Hoogerbrugge P, Bökkerink JP, Pieters R, Corbett R, Österlundh G, Behrendtz M, Holmqvist BM, Hjorth L, Petersen C, Jakobson Å, Hjalmars U, Ljungman G, Angst R, Kühne T, Paulussen M, Leyvraz S, Rischewski J, Feldges A, Greiner J, Hess U, Exner GU, Niggli F, Knuth A, King D, McCarthy A, Henry P, Morland B, Rees H, Nicholson J, Traunecker H, Wallace H, Ronghe M, Simpson E, Cowie F, White J, Picton S, Lewis I, Leahy M, Stark D, Selby PJ, Heney D, Pizer B, McDowell H, Michalski A, Whelan J, Chisholm J, Pritchard-Jones K, Judson I, Brennan B, Hale J, Verrill M, Walker D, Sokal M, Wheeler K, Lee V, Gerrard M, Woll P, Lorigan P, Robinson M, Kohler J. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. Eur J Cancer. 2015 Nov;51(16):2453-64.  

81. Kratzer W, Gruener B, Kaltenbach TE, Ansari-Bitzenberger S, Kern P, Fuchs M, Mason RA, Barth TF, Haenle MM, Hillenbrand A, Oeztuerk S, Graeter T. Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: Echinococcosis multilocularis Ulm classification-ultrasound. World J Gastroenterol. 2015 Nov;21(43): 12392-402.

80. Sander S, Chu VT, Yasuda T, Franklin A, Graf R, Calado DP, Li S, Imami K, Selbach M, Di Virgilio M, Bullinger L, Rajewsky K. PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones.  Immunity. 2015 Dec 15;43(6):1075-86. Epub 2015 Nov 24.

79. Hofmann S, Mead A, Malinovskis A, Hardwick NR, Guinn BA. Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunol Immunother. 2015 Nov;64(11): 1357-67.

78. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR, Morley W, Clegg S, Frost G. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015 Nov;64(11):1744-54.

77. Kurth F, Develoux M, Mechain M, Clerinx J, Antinori S, Gjørup IE, Gascon J, Mørch K, Nicastri E, Ramharter M, Bartoloni A, Visser L, Rolling T, Zanger P, Calleri G, Salas-Coronas J, Nielsen H, Just-Nübling G, Neumayr A, Hachfeld A, Schmid ML, Antonini P, Pongratz P, Kern P, Saraiva da Cunha J, Soriano-Arandes A, Schunk M, Suttorp N, Hatz C, Zoller T; TropNet Severe Malaria Investigator Group. Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study. Clin Infect Dis.  2015 Nov 1;61(9):1441-4.

76. Buske C, Kirchhoff F, Münch J. EPI-X4, a novel endogenous antagonist of CXCR4. Oncotarget. 2015 Nov 3;6(34):35137-8.

75. Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M, Eichhorst B. Outcome of advanced chronic lymphocytic leukemia following different firstline- and relapse-therapies: A metaanalysis of five prospective trials of the German CLL Study Group (GCLLSG). Haematologica. 2015 Nov;100(11):1451-9.

74. Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A, Bullinger L, Hofmann S, Götz M, Döhner K, Ihme S, Döhner H, Buske C, Feuring-Buske M, Greiner J.  Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int J Cancer. 2015 Nov 1;137(9):2083-92. 

73. Viardot A, Herfarth K, Dreyling . Indolent lymphoma. Therapy strategies. Onkologe. 2015 Oct;21(10): 936-945.

72. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22;526(7574):525-30.

71. Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, Beutner D, Rosenwald A, Stilgenbauer S, Hallek M, Benner A, Herling M. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 2015 Oct;29(10):2003-14.

70. Lennerz JK, Hoffmann K, Bubolz AM, Lessel D, Welke C, Rüther N, Viardot A, Möller P. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma. Oncotarget. 2015 Oct 6;6(30):29097-110.

69. Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F. MicroRNA-223 dose-levels fine-tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol. 2015 Oct;43(10):858-868.e7.

68. Wagener R, Aukema SM, Schlesner M, Haake A, Burkhardt B, Claviez A, Drexler HG, Hummel M, Kreuz M, Loeffler M, Rosolowski M, López C, Möller P, Richter J, Rohde M, Betts MJ, Russell RB, Bernhart SH, Hoffmann S, Rosenstiel P, Schilhabel M, Szczepanowski M, Trümper L, Klapper W, Siebert R, ICGC MMML-Seq-Project , "Molecular Mechanisms in Malignant Lymphomas" Network Project of the Deutsche Krebshilfe , Richter G, Siebert R, Wagner S, Haake A, Richter J, Eils R, Lawerenz C, Radomski S, Scholz I, Borst C, Burkhardt B, Claviez A, Dreyling M, Eberth S, Einsele H, Frickhofen N, Haas S, Hansmann ML, Karsch D, Kneba M, Lisfeld J, Mantovani-Löffler L, Rohde M, Stadler C, Staib P, Stilgenbauer S, Ott G, Trümper L, Zenz T, Hansmann ML, Kube D, Küppers R, Weniger M, Haas S, Hummel M, Klapper W, Kostezka U, Lenze D, Möller P, Rosenwald A, Szczepanowski M, Ammerpohl O, Aukema SM, Binder V, Borkhardt A, Haake A, Hezaveh K, Hoell J, Leich E, Lichter P, Lopez C, Nagel I, Pischimariov J, Radlwimmer B, Richter J, Rosenstiel P, Rosenwald A, Schilhabel M, Schreiber S, Vater I, Wagner R, Siebert R, Bernhart SH, Binder H, Brors B, Doose G, Eils J, Eils R, Hoffmann S, Hopp L, Kretzmer H, Kreuz M, Korbel J, Langenberger D, Loeffler M, Radomski S, Rosolowski M, Schlesner M, Stadler PF, Sungalee S, Barth TF, Bernd HW, Cogliatti SB, Feller AC, Hansmann ML, Hummel M, Klapper W, Lenze D, Möller P, Müller-Hermelink HK, Ott G, Rosenwald A, Stein H, Szczepanowski M, Wacker HH, Barth TF, Behrmann P, Daniel P, Dierlammm J, Haralambieva E, Harder L, Holterhus PM, Küppers R, Kube D, Lichter P, Martín-Subero JI, Möller P, Murga-Peñas EM, Ott G, Pott C, Pscherer A, Rosenwald A, Schwaenen C, Siebert R, Trautmann H, Vockerodt M, Wessendorf S, Bentink S, Berger H, Hasenclever D, Kreuz M, Loeffler M, Rosolowski M, Spang R, Stürzenhofecker B, Trümper L, Wehner M, Loeffler M, Siebert R, Stein H, Trümper L. The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma. Genes Chromosomes Cancer. 2015 Sep;54(9): 555-64.

67. Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia. 2015 Sep;29(9):1942-5. No abstract available.

66. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v100-v107. Review. No abstract available.

65. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v85-v99. Review. No abstract available.

64. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v78-v84. No abstract available.

63. Laban S, Doescher J, Schuler PJ, Bullinger L, Brunner C, Veit JA, Hoffmann TK. [Immunotherapy of head and neck tumors : Highlights of the ASCO Meeting 2015]. HNO. 2015 Sep;63(9):612-9.

62. Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL Study Group. Leuk Lymphoma. 2015 Sep 17:1-21.

61. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52.

60. Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez A, Dimitrova L, Haas S, Hoell JI, Hummel M, Karsch D, Klapper W, Kleo K, Kretzmer H, Kreuz M, Küppers R, Lawerenz C, Lenze D, Loeffler M, Mantovani-Löffler L, Möller P, Ott G, Richter J, Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schneider M, Scholz I, Stilgenbauer S, Stunnenberg HG, Szczepanowski M, Trümper L, Weniger MA; ICGC MMML-Seq Consortium, Hoffmann S, Siebert R, Iaccarino I. MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5261-70.

59. von Witzleben A, Goerttler LT, Marienfeld R, Barth H, Lechel A, Mellert K, Böhm M, Kornmann M, Mayer-Steinacker R, von Baer A, Schultheiss M, Flanagan AM, Möller P, Brüderlein S, Barth TF. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell Cycle Pathway. Cancer Res. 2015 Sep 15;75(18):3823-31.

58. Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia. 2015 Sep;29(9):1942-5. No abstract available.

57. Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood. 2015 Sep 3;126(10):1214-23.

56. Maaß C, Kletting P, Bunjes D, Mahren B, Beer AJ, Glatting G. Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody Radioimmunotherapy. Cancer Biother Radiopharm. 2015 Sep;30(7):285-290.

55. Baer C, Oakes CC, Ruppert AS, Claus R, Kim-Wanner SZ, Mertens D, Zenz T, Stilgenbauer S, Byrd JC, Plass C. Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia. Int J Cancer. 2015 Sep;137(6):1352-61.

54. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45.

53. Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015 Aug;29(8):1695-701.

52. Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: Primary results of the CLL9 trial of the German CLL Study Group. Leuk Lymphoma. 2015 Aug 21:1-22.

51. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45.

50. Wuestenberg J, Gruener B, Oeztuerk S, Mason RA, Haenle MM, Graeter T, Akinli AS, Kern P, Kratzer W. Diagnostics in cystic echinococcosis: serology versus ultrasonography. Turk J Gastroenterol. 2014 Aug;25(4):398-404.

49. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant. 2015 Aug;50(8):1057-62.

48. Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmenn P, Trněný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug;100(8):e311-4.

47. Mora-Jensen H, Jendholm J, Rapin N, Klarskov Andersen M, Roug AS, Otzen Bagger F, Bullinger L, Winther O, Borregaard N, Porse BT, Theilgaard-Mönch K. Cellular origin of prognostic chromosomal aberrations in AML patients. Leukemia. 2015 Aug;29(8):1785-9.

46. Knas T, Buck M, Stegelmann F, Möller P, Barth TF. [Detection of the BCR-ABL fusion: Comparative analysis of six commercially available FISH fusion probes]. Pathologe. 2015 Jul;36(4): 372-84.

45. Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015 Jul 9;523(7559):183-8.

44. Kortüm KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol. 2015 Jul;94(7):1205-11.

43. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9.

42. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015 Jul 16;126(3):319-27.

41. Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM, Eichhorst B, Hallek M. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015 Jul;11(13):1895-903. 

40. Richter PJ, Holtfreter M, Orhun A, Müller-Stöver I, Kubitz R, Hillenbrand A, Kratzer W, Gräter T, Grüner B. [Echinococcosis]. MMW Fortschr Med. 2015 Jun;157(12): 56-63.

39. Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung , German CML Study Group , Wernli M, Bargetzi M, Fischer von Weikersthal L, Gro V, Müller S, Hahn M, Schlimok G, Reichert D, Janssen J, Furkert J, Mandel T, Majunke PJ, Paliege R, Reichert P, Fuss H, Neben K, Staiger HJ, Heim D, Gratwohl A, Tichelli A, Korsten S, Henesser D, Le Coutre P, Arnold R, Ludwig WD, Ratei R, Teutsch C, Ludwig F, Urmersbach A, Blau I, Ihle H, Sperling C, Schelenz C, Koschuth A, Kingreen D, Heßling J, Derwahl KM, Oldenkott B, Englisch HJ, Ludwig F, Thiel E, Burmeister T, Notter M, de Wit M, Rothaug W, Büschel G, Beyer J, Dahmen E, Biaggi C, Lämmle B, Friess D, Baerlocher G, Oppliger Leibundgut E, Tobler A, Just M, Schäfer E, Behringer D, Brandt M, Schmiegel W, Vaupel HA, Verbeek W, Ko YD, Weidenhöfer S, Sauerbruch T, Hahn-Ast C, Janzen V, Schmidt-Wolf I, Trenn G, van der Linde M, Pommerien W, Fritz L, Krauter J, Lordick F, Fritsch G, Pflüger KH, Diekmann C, Kullmer J, Doering G, Munzinger H, Hertenstein B, Peyn A, Mayer J, Zácková D, Kujickova J, Stier S, Wejda B, Möller-Faßbender F, Hänel M, Morgner A, Herbst R, Matek W, Lamberti C, Zöller T, Koch B, Marth T, Henzel A, Wagner S, Woska E, Neumann F, Hoffknecht MM, Illmer T, Wolf T, Ehninger G, Kiani A, Platzbecker U, Aul C, Badrakhan CD, Giagounidis A, Flaßhove M, Henneke F, Moritz T, Simon M, Müller LL, Janz R, Eckart M, Häcker B, Rech D, Mackensen A, Krause SW, Staib P, Schlegel F, Wätzig K, Rudolph R, Wattad M, Baur FK, Heit W, Beelen DW, Hüttmann A, Novotny J, Trenschel R, Lindemann A, Linck D, Jäger E, Al-Batran SE, Ottmann OG, Serve H, Reiber T, Semsek D, Waller C, Kühnemund A, Hoeffkes HG, Lambertz H, Schulz L, Tajrobehkar K, Mittermüller J, Rummel MJ, Burchardt A, Pralle H, Runde V, Klei M, Westheider J, Hoyer A, Tessen HW, Hesse A, Trümper L, Binder C, Schmidt CA, Hirt C, Sieber M, Eschenburg H, Wilhelm S, Depenbusch R, Rösel S, Eimermacher H, Spohn C, Moeller R, Schmitz N, Nickelsen M, Engel E, Haatanen T, Hollburg W, Platz D, Köster H, Bokemeyer C, Schafhausen P, Grote-Metke A, Bechtel B, Hemeier M, Sosada M, Ganser A, Schlegelberger B, Ho AD, Rohlfing S, Dengler J, Petersen V, Porowski P, Hahn L, Dietzfelbinger H, Gröschel W, Bartholomäus A, Pfreundschuh M, Kemmerling M, Hansen R, Reeb M, Link H, Mahlmann S, Mezger J, Schatz M, Schmier M, Gatter J, Neumann S, Heymanns J, Steinmetz HT, Schmitz S, Scheid C, Planker M, Frieling T, Lollert A, Neise M, Schröder M, Greif D, Kempf B, März W, Kremers S, Müller L, Hartmann F, Heil G, Goldmann B, Heinkele P, Gregor M, Theobald M, Fischer T, Thomas S, Hensel M, Plöger C, Schuster D, Brust J, Hieber U, Hehlmann R, Neubauer A, Burchert A, Graeven U, Lange C, Schmidt G, Völkl S, Schmidt B, Hitz H, Spiekermann K, Hiddemann W, Haferlach T, Haferlach C, Schnittger S, Stötzer O, Scheidegger C, Fischer C, Berdel WE, Koppele A, Hebart H, Snaga A, Schmidt P, Hoffmann R, Reschke D, Zirpel I, Sauer M, Lenk G, Eimermacher H, Theilmann L, Sandritter B, Schenk M, Dengler R, Herr W, Krause S, Braun B, Günther E, Wacker A, Pihusch R, Baldus M, Matzdorff A, Pollmeier G, Grimminger W, Hebart H, Geer T, Schanz S, Jür C, Gassmann W, Seitz K, Kaesberger J, Mück R, Illerhaus G, Denzlinger C, Fiechtner H, Springer G, Hoffmann D, Jacki SH, Kanz L, Bross-Bach U, Döhner H, Stegelmann F, Kalhori N, Langer W, Nusch A, Wei J, Kamp T, Schadeck-Gressel C, Schwerdtfeger R, Josten KM, Klein O, Fett W, Strotkötter H, Maintz C, Groschek M, Schlag R, Elsel W, Schüler F, Dölken G, Lindemann HW, Wolf HH, Schmoll HJ, Braumann D, Hoelzer P, Kleeberg U, Hossfeld D, Lange E, Schubert J, Weischer H, Dürk HA, Kirchner HH, Bu EC, Sievers B, Freier W, Kaiser U, Peest D, Römer E, Hermann T, Fauser A, Valverde ML, Menzel J, Kemper J, Hochhaus A, La Rosée P, Bentz M, Wilhelm S, Prümmer O, Kneba M, Strack U, Schoch R, Severin K, Stauch M, Karbach U, Vehling-Kaiser U, Köchling G, Wei U, Middeke H, Neuhaus T, Martin H, Fetscher S, Schmielau J, Kämpfe D, Uppenkamp M, Wei B, Thum P, Wuillemin W, Hofmann WK, Griesshammer M, Tischler HJ, Becker M, Hanfstein B, Müller M, Saußele S, Lunscken C, Kolb HJ, Lutz L, Hentrich M, Nerl C, Wendtner C, Berdel WE, Ladda E, Gnad M, Suna H, Schmidt E, Koschmieder S, Falge C, Wandt H, Wilhelm M, Köhne CH, Schweiger C, Müller-Naendrup C, Frühauf S, Ranft K, Theilmann L, Dencausse Y, Baake G, Ritter PR, Kloke O, Becker M, Göttler B, Völkl S, Schick HD, Weidenhöfer S, Weidinger P, Wacker D, Wehmeyer J, Kreuser ED, Schlenska-Lange A, Edinger R, Andreesen R, Wehmeier A, Stahlhut K, Käfer G, Cerny T, Hess U, Priebe-Richter C, Stange-Budumlu O, Demandt M, Freunek G, Heidemann E, Schleicher J, Mergenthaler HG, Boewer C, Zeller C, Laubenstein HP, Rendenbach B, Clemens M, Waladkhani AR, Forstbauer H, Müller F, Brettner S, Raghavachar A, Kunzmann V, Goebeler ME, Gmür J. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. PLoS ONE. 2015 Jun;10(6): e0129648.

38. Kayser S, Walter RB, Stock W, Schlenk RF. Minimal Residual Disease in Acute Myeloid Leukemia-Current Status and Future Perspectives. Curr Hematol Malig Rep. 2015 Jun;10(2):132-44. 

37. Stilgenbauer S, Furman RR, Zent CS. Management of Chronic Lymphocytic Leukemia. Am Soc Clin Oncol Educ Book. 2015;35:164-175.

36. Buske C, Seymour J. Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment. Leuk Lymphoma. 2015 Jun 9:1-6. No abstract available.

35. Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T. Health-related quality of life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015 Jun;100(6):826-33.

34. Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk RF. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br J Haematol. 2015 Jun;169(5):694-700.

33. Kern P. Series: Immune Response to Parasitic Infections (Volume 2) Immunity to Helminths and Novel Therapeutic Approaches. Clin Infect Dis. 2015 Jun 1;60(11):1734.

32. Lerch K, Meyer AH, Stroux A, Hirt C, Keller U, Viardot A, Marks R, Schreiber S, Pezzutto A, Scholz CW. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Ann Hematol. 2015 Jun;94(6):981-8.

31. Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH, Fischer T. Epo-induced erythroid maturation is dependent on Plcγ1 signaling. Cell Death Differ. 2015 Jun;22(6):974-85.

30. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5): 1123-32.

29. Grishina O, Schmoor C, Döhner K, Hackanson B, Lubrich B, May AM, Cieslik C, Müller MJ, Lübbert M. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer. 2015 May 26;15(1):430.

28. Meffert C, Gaertner J, Seibel K, Jors K, Bardenheuer H, Buchheidt D, Mayer-Steinacker R, Viehrig M, Paul C, Stock S, Xander C, Becker G. Early Palliative Care-Health services research and implementation of sustainable changes: the study protocol of the EVI project. BMC Cancer. 2015 May 29;15(1):443.

27. Schneider D, Dühren-von Minden M, Alkhatib A, Setz C, van Bergen CA, Benkißer-Petersen M, Wilhelm I, Villringer S, Krysov S, Packham G, Zirlik K, Römer W, Buske C, Stevenson FK, Veelken H, Jumaa H. Lectins from opportunistic bacteria interact with acquired variable region glycans of surface Ig in follicular lymphoma. Blood. 2015 May 21;125(21):3287-96.

26. Willer A, Jakobsen JS, Ohlsson E, Rapin N, Waage J, Billing M, Bullinger L, Karlsson S, Porse BT. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia. Leukemia. 2015 May;29(5):1018-31.

25. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May;39(5):495-500.

24. Graeter T, Ehing F, Oeztuerk S, Mason RA, Haenle MM1, Kratzer W, Seufferlein T, Gruener B. Hepatobiliary complications of alveolar echinococcosis: A long-term follow-up study. World J Gastroenterol. 2015 Apr 28;21(16):4925-32.

23. Döhner K, Paschka P, Döhner H. [Acute myeloid leukemia]. Internist (Berl). 2015 Apr;56(4):354-63. German.

22. Kaltenmeier C, Gawanbacht A, Beyer T, Lindner S, Trzaska T, van der Merwe JA, Härter G, Grüner B, Fabricius D, Lotfi R, Schwarz K, Schütz C, Hönig M, Schulz A, Kern P, Bommer M, Schrezenmeier H, Kirchhoff F, Jahrsdörfer B. CD4+ T Cell-Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme B-Expressing Regulatory B Cells in HIV Patients. J Immunol. 2015 Apr 15;194(8):3768-77.

21. Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015 Apr;100(4):511-6.

20. Kayser S, Schlenk RF, Grimwade D, Yosuico VE, Walter RB. Minimal residual disease-directed therapy in acute myeloid leukemia. Blood. 2015 Apr 9;125(15):2331-2335.

19. Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann W, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2015 Apr;100(4):e122-4.

18. Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M. T cell-based targeted immunotherapies for patients with multiple myeloma. Int J Cancer. 2015 Apr 15;136(8):1751-68.

17. Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Joanna Baxter E, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015 Apr 7;6:6691.

16. Weißbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S, Leich E. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2015 Apr;169(1):57-70.

15. Tam CS, Stilgenbauer S. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? Leuk Lymphoma. 2015 Mar;56(3):587-93.

14. Paschka P, Schlenk RF, Gaidzik VI, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K. ASXL1 mutations in younger adult patients with acute myeloid leukemia: A study of the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica. 2015 Mar;100(3):324-30.

13. Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, Bunjes DW, Zhang MJ. Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9.

12. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015 Feb;5: 8535.

11. Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3 P) in -17p high risk disease. Br J Haematol. 2015 Feb;168(4):507-10.

10. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015 Feb;29(2):329-36.

9. Kaltenbach TE, Graeter T, Mason RA, Kratzer W1, Oeztuerk S, Haenle MM, Gruener B, Gottstein M. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET-CT. Nuklearmedizin. 2015 Feb 16;54(1):43-9.

8. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR. Effect of Mutation Order on Myeloproliferative Neoplasms. N Engl J Med. 2015 Feb 12;372(7):601-612.

7. Veloso Alves Pereira I, Buchmann B, Sandmann L, Sprinzl K, Schlaphoff V, Döhner K, Vondran F, Sarrazin C, Manns MP, Pinto Marques Souza de Oliveira C, Sodeik B, Ciesek S, von Hahn T. Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP). PLoS One. 2015 Feb 3;10(2):e0117152.

6. Eschbach J, von Einem B, Müller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, Weydt P, Otto M, Fauler M, Liss B, McLean PJ, Spada AR, Ludolph AC, Weishaupt JH, Danzer KM. Mutual exacerbation of peroxisome proliferator-activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization. Ann Neurol. 2015 Jan;77(1): 15-32.

5. Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, Nagler A, Blaise D, Rocha V, Cornelissen JJ, Mohty M. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia. 2015 Jan;29(1):51-7. 

4. Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, Bindels EM, Beverloo HB, Döhner H, Löwenberg B, Döhner K, Delwel R, Valk PJ. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood. 2015 Jan 1;125(1):133-9.

3. Bhattacharya N, Reichenzeller M, Caudron-Herger M, Haebe S, Brady N, Diener S, Nothing M, Döhner H, Stilgenbauer S, Rippe K, Mertens D. Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. Int J Cancer. 2015 Jan 1;136(1):65-73.

2. Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncol Res Treat. 2015;38(4):185-92.

1. Hunt L, Greenwood D, Heimpel H, Noel N, Whiteway A, King MJ. Toward the harmonization of result presentation for the eosin-5'-maleimide binding test in the diagnosis of hereditary spherocytosis. Cytometry B Clin Cytom. 2015 Jan;88(1): 50-7.